Optimal strength and timing of steroids in the management of erlotinib-related skin toxicities in a post-marketing surveillance study (POLARSTAR) of 9909 non-small-cell lung cancer patients
Crossref DOI link: https://doi.org/10.1007/s10147-015-0893-5
Published Online: 2015-10-26
Published Print: 2016-04
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Yamazaki, Naoya
Kiyohara, Yoshio
Kudoh, Shoji
Seki, Akihiro
Fukuoka, Masahiro
Funding for this research was provided by:
F. Hoffman-La Roche (CH) (NA)
License valid from 2015-10-26